Comparison of Antifungal Prophylaxis Drugs in Patients With Hematological Disease or Undergoing Hematopoietic Stem Cell Transplantation | Zendy

Jing Wang | Zendy; Min Zhou | Zendy; Jingyan Xu | Zendy; Rongfu Zhou | Zendy; Bing Chen | Zendy; Yuan Wan | Zendy

Open Access

Comparison of Antifungal Prophylaxis Drugs in Patients With Hematological Disease or Undergoing Hematopoietic Stem Cell Transplantation

Author(s) -

Jing Wang,

Min Zhou,

Jingyan Xu,

Rongfu Zhou,

Bing Chen,

Yuan Wan

Publication year - 2020

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2020.17652

Subject(s) - medicine , adverse effect , hematopoietic stem cell transplantation , randomized controlled trial , meta analysis , transplantation , clinical trial , intensive care medicine

Key Points Question What primary antifungal prophylaxis drugs for patients with hematological disease or undergoing hematopoietic stem cell transplantation perform best in randomized clinical trials? Findings In this systematic review and network meta-analysis of 69 randomized clinical trials that performed comparisons of individual antifungal agents in 14 789 patients, voriconazole was recommended for patients undergoing HSCT and posaconazole was recommended for patients with acute myeloid leukemia or myelodysplastic syndrome. Meaning These findings may help clinicians to make antifungal prophylaxis treatment decisions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research